UNITY Biotechnology Program Update on ENVISION, the Phase 2 Clinical Trial of UBX1325 in Patients with Wet AMD
About The Event
Join us for a virtual program update with UNITY Biotechnology, featuring retinal expert Arshad M. Khanani, MD, MA, FASRS (Director of Clinical Research, Sierra Eye Associates) who will discuss the current treatment landscape for patients with wet age-related macular degeneration (wet AMD) and provide a program update on ENVISION, the Phase 2 clinical trial of UBX1325 in this patient population.
UBX1325 is a potent Bcl-xL inhibitor designed to selectively eliminate the senescent cells accumulating in diseased blood vessels of the eye and is also being evaluated by UNITY in diabetic macular edema and diabetic retinopathy.
A live question and answer session will follow the formal presentations.